home / stock / acad / acad quote
Last: | $16.31 |
---|---|
Change Percent: | 0.54% |
Open: | $16.5 |
Close: | $16.31 |
High: | $16.51 |
Low: | $16.16 |
Volume: | 1,639,036 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$16.31 | $16.5 | $16.31 | $16.51 | $16.16 | 1,639,036 | 04-25-2024 |
$16.59 | $16.81 | $16.59 | $16.86 | $16.55 | 1,163,106 | 04-24-2024 |
$16.74 | $17.09 | $16.74 | $17.24 | $16.605 | 1,476,022 | 04-23-2024 |
$16.99 | $17.05 | $16.99 | $17.34 | $16.94 | 1,156,988 | 04-22-2024 |
$16.82 | $16.98 | $16.82 | $17.295 | $16.62 | 3,628,011 | 04-19-2024 |
$17.07 | $17.26 | $17.07 | $17.35 | $17.01 | 988,365 | 04-18-2024 |
$17.19 | $17.25 | $17.19 | $17.25 | $16.97 | 1,027,814 | 04-17-2024 |
$17.08 | $16.75 | $17.08 | $17.2 | $16.6 | 978,294 | 04-16-2024 |
$16.89 | $17.13 | $16.89 | $17.28 | $16.765 | 1,112,106 | 04-15-2024 |
$17.14 | $17.4 | $17.14 | $17.615 | $16.85 | 1,296,092 | 04-12-2024 |
$17.41 | $17.9 | $17.41 | $17.9 | $17.34 | 1,521,802 | 04-11-2024 |
$17.73 | $17.72 | $17.73 | $17.77 | $17.55 | 1,147,291 | 04-10-2024 |
$18.15 | $17.94 | $18.15 | $18.245 | $17.84 | 1,371,820 | 04-09-2024 |
$17.8 | $17.87 | $17.8 | $18.08 | $17.63 | 1,725,485 | 04-08-2024 |
$18.01 | $17.91 | $18.01 | $18.25 | $17.61 | 1,522,875 | 04-05-2024 |
$18.05 | $18.52 | $18.05 | $18.63 | $18.02 | 1,167,947 | 04-04-2024 |
$18.42 | $18 | $18.42 | $18.465 | $18 | 1,334,396 | 04-03-2024 |
$18.11 | $18.04 | $18.11 | $18.25 | $17.86 | 1,276,398 | 04-02-2024 |
$18.26 | $18.59 | $18.26 | $18.59 | $17.91 | 1,243,033 | 04-01-2024 |
$18.49 | $18.2 | $18.49 | $18.5 | $18.05 | 1,531,606 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
ACADIA Pharmaceuticals Inc. Company Name:
ACAD Stock Symbol:
NASDAQ Market:
ACADIA Pharmaceuticals Inc. Website:
Company to host conference call and webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. A...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission. “Re...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO. The presentations inclu...